INVESTORS

Investors Overview:

To date, Promentis has raised more than $31M total in equity financing, with the most recent Series C financing totaling $26 million.

INVESTORS

aisling-capital

Black_Pearl_Investments

GRANT AWARDS

TECHNOLOGY

Novel oral compounds engaging SystemX_C-, a CNS target for diverse psychiatric disorders
LEARN MORE

PRESS RELEASES

Promentis Pharmaceuticals to Present at the 11th Anniversary CNS Summit
October 31, 2020
Promentis Pharmaceuticals to Present at the 10th Anniversary CNS Summit
November 1, 2019
Promentis Pharmaceuticals Announces Positive Results for Phase 2A Study of SXC-2023 Targeting Novel Glutamatergic Mechanism and Completion of Enrollment for Phase 2 Trichotillomania Study
October 31, 2019
Promentis Pharmaceuticals Announces Commencement of Phase 2 Studies for SXC-2023 Targeting Novel Glutamatergic Mechanism
January 17, 2019